Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

26.46 -0.32 (-1.19%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference
Via ACCESSWIRE
News headline image
Can This Company's Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems? ↗
There is a high probability that you may know someone battling some form of addiction. Whether it’s a problem with opioids, alcohol, cocaine, or even using pain meds, an unchecked addiction can be... 
Via Benzinga
News headline image
Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2022
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022
Via ACCESSWIRE
News headline image
Intercept Pharmaceutical Stock Sees RS Rating Rise To 91 ↗
Intercept Pharmaceutical shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
News headline image
Recursion Pharma Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark ↗
Recursion Pharma stock cleared a key performance benchmark Monday, with its Relative Strength Rating upgraded to 89 from 76 the day before. 
Via Investor's Business Daily
News headline image
7 Safe Stocks to Rely on When the Market Swerves ↗
As volatility and uncertainty continue, it remains a good time to add these seven safe stocks to your portfolio. 
Via InvestorPlace
News headline image
Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals's Return on Invested Capital Overview ↗
Pulled from Benzinga Pro data, Amphastar Pharmaceuticals (NASDAQ:AMPH) showed a loss in earnings since Q1, totaling $17.35 million. Sales, on the other hand, increased by 2.57% to $123.47 million... 
Via Benzinga
News headline image
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes
Via ACCESSWIRE
News headline image
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review ↗
The major indexes continued to advance, despite some key warnings. 
Via Investor's Business Daily
News headline image
Amphastar Pharmaceuticals: Q2 Earnings Insights ↗
  Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill ↗
Amphastar came in well above forecasts, while Syndax had fewer than expected losses. 
Via Investor's Business Daily
News headline image
Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
On Monday, Kura Oncology stock had its Relative Strength (RS) Rating upgraded to 91, up from 85 a day earlier. 
Via Investor's Business Daily
News headline image
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022
Via ACCESSWIRE
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022 ↗
  
Via Benzinga
News headline image
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings ↗
IBD 50 member Amphastar Pharmaceuticals stock is expected to report on Aug. 9 and is trading approximately 12% below a 42.41 entry. 
Via Investor's Business Daily
News headline image
Amphastar Receives FDA Approval for Vasopressin
Via ACCESSWIRE
News headline image
Amphastar Receives FDA Approval for Vasopressin
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 19, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
News headline image
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating ↗
Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
News headline image
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5 ↗
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
News headline image
Prometheus Biosciences Stock Shows Rising Relative Strength ↗
Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90. 
Via Investor's Business Daily
News headline image
Merus Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
On Thursday, Netherlands-based Merus stock had its Relative Strength (RS) Rating upgraded to 94 from 78 a day earlier. 
Via Investor's Business Daily
News headline image
Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗
ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level. 
Via Investor's Business Daily
News headline image
Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
On Monday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 91 Monday, up from 85 a day earlier. 
Via Investor's Business Daily
News headline image
Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8% ↗
Among its other key ratings, Amsterdam-based gene therapy company Uniqure stock also has a 92 Composite Rating. 
Via Investor's Business Daily
News headline image
Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91 ↗
Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91. 
Via Investor's Business Daily
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.